LALREAN

Lalrean is an early-stage biotechnology company focused on developing novel small molecule therapeutics for neuropsychiatric disorders. The company's lead research program centers on the development of G protein-coupled receptor 139 (GPR139) agonists, which are being investigated for the treatment of the negative symptoms of schizophrenia. By targeting GPR139, Lalrean aims to address significant unmet needs in mental health where current antipsychotic treatments often fail to improve social withdrawal and cognitive deficits. The company operates primarily in the pre-clinical discovery phase, leveraging expertise in medicinal chemistry and neuroscience.